NCT00858468View on ClinicalTrials.gov

Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

394

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

June 30, 2006

Study Completion Date

December 31, 2006

Conditions

Influenza

Interventions

BIOLOGICAL

Influenza virus vaccine (2004-2005 Formulation)

0.25 mL, Intramuscular

BIOLOGICAL

Influenza virus vaccine (2004-2005 Formulation)

0.25 mL, Intramuscular

Trial Locations (8)

15241

Pittsburgh

23510

Norfolk

27705

Durham

30062

Marietta

44308

Akron

45404

Dayton

72205

Little Rock

98101

Seattle

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00858468 - Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age | Biotech Hunter | Biotech Hunter